PURPOSE: The efficacy of the combination of finasteride and flutamide in select patients with advanced prostatic cancer is determined. MATERIALS AND METHODS: A total of 22 sexually active patients with stages C and D1 carcinoma of the prostate was treated with finasteride plus flutamide. Mean followup was 22 months. RESULTS: Initial mean prostate specific antigen level was 42.9 ng./ml. At 3 and 6 months, the mean prostate specific antigen level was 3.6 ng./ml. and 2.9 ng./ml., respectively. The results appear durable at 24 months. Side effects were minimal, with 86% of the men maintaining sexual function. CONCLUSIONS: Finasteride plus flutamide should be considered in sexually active patients with minimal volume advanced prostate cancer.
PURPOSE: The efficacy of the combination of finasteride and flutamide in select patients with advanced prostatic cancer is determined. MATERIALS AND METHODS: A total of 22 sexually active patients with stages C and D1 carcinoma of the prostate was treated with finasteride plus flutamide. Mean followup was 22 months. RESULTS: Initial mean prostate specific antigen level was 42.9 ng./ml. At 3 and 6 months, the mean prostate specific antigen level was 3.6 ng./ml. and 2.9 ng./ml., respectively. The results appear durable at 24 months. Side effects were minimal, with 86% of the men maintaining sexual function. CONCLUSIONS:Finasteride plus flutamide should be considered in sexually active patients with minimal volume advanced prostate cancer.
Authors: Ned J Place; Elizabeth M Coscia; Nancy J Dahl; Christine M Drea; Kay E Holekamp; Janet F Roser; Cheryl L Sisk; Mary L Weldele; Stephen E Glickman Journal: Gen Comp Endocrinol Date: 2010-10-29 Impact factor: 2.822
Authors: J Paul Monk; Susan Halabi; Joel Picus; Arif Hussain; George Philips; Ellen Kaplan; Tim Ahles; Lin Gu; Nicholas Vogelzang; William K Kelly; Eric J Small Journal: Cancer Date: 2011-12-16 Impact factor: 6.860